FLOWER MOUND, Texas, Nov. 19 AmericanHealthChoice, Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, amedical services company with medical clinics in Texas and Tennessee, ispleased to announce the first sales of the U.S. FDA approved OmniBody Scan, aninfrared thermal imaging camera that detects patterns of abnormality withinthe human body and identifies problems early enough for prevention andtreatment.
"Physicians purchasing these first systems have been trained and moresystems will be sold soon," said Dr. Joseph W. Stucki, CEO. "We are alsopleased to announce that our new and updated web site, explaining the productand its myriad uses, has been activated at:http://www.omnibodyscan.com
"AMHI also has signed a distribution agreement covering the State of Texasfor the purchase of a minimum of 15 cameras annually," Dr. Stucki said. "Wehave spoken to a number of oncologists who are very excited about the medicalinfrared technology we are bringing to the health care sector. I am confidentthat we will be successful in negotiating exclusive distribution agreements inother states, Canada, Mexico and elsewhere."
The OmniBody Scan is a non-invasive tool with no harmful side effects. Itis manufactured exclusively for American HealthChoice by a respected infraredimaging manufacturer with years of successful experience in this field. "Ourproduct adheres to the highest standards of thermography. It is easy to useand offers a very high grade of technology and quality. With its infraredtechnology, it allows an oncologist to find cancers, including breast cancer,years away from becoming a mass large enough to be detected by mammography, CTscans, MRIs or Ultrasound," Dr. Stucki said.
Thermography uses infrared technology to capture a picture of the body'simage without the use of radiation or invasive technology. Data on the body'sskin temperature is sent to a computer that converts the patterns to imageswhich are read by a physician looking for abnormalities. As cancer grows, itsneed for nutrients increases and this activity causes increases intemperatures (neoangiogenesis). These temperature variations, caught by theinfrared imaging, can be an early sign of cancer or pre-cancerous activity.
Finally, the Company is pleased to announce that Dr. Trip Chaudhury, M.D.,Board Certified in Oncology, with practices in Beaumont and Houston, whocompleted a dissertation in Medical School on neoangiogenisis, has joined theCompany's Advisory Board. "He is a perfect fit for our Advisory Board," Dr.Stucki said.CONTACT: Dr. J.W. Stucki, CEO American HealthChoice, Inc. 817/837-8000 Paul Knopick E & E Communications 949/707-5365 [email protected]
SOURCE American HealthChoice, Inc.